Core Viewpoint - Guangzheng Eye Hospital announced progress on comprehensive credit and guarantee matters for its subsidiaries, indicating a strategic move to secure financial support for operations and growth [1] Group 1: Credit and Guarantee Details - In April 2025, a meeting approved the proposal for the company and its controlling subsidiaries to apply for a comprehensive credit limit not exceeding 650 million yuan from financial institutions [1] - The shareholders' meeting in May approved the proposal to provide mutual guarantees totaling no more than 650 million yuan [1] - Recently, its wholly-owned subsidiaries, Zhongxing Eye Hospital and New Vision Eye Hospital, applied for a credit limit of 30 million yuan from the Shanghai branch of China Merchants Bank, with the company and related parties providing joint liability guarantees [1] Group 2: Financial Impact - Following this guarantee, the total guarantee amount for the company and its subsidiaries reached 51.109 million yuan, which accounts for 453.50% of the latest audited net assets attributable to the parent company [1] - All guarantees are internal mutual guarantees, with no external guarantee risks involved [1]

Core Points - The company, Guangzheng Eye Hospital, announced the convening of its second extraordinary general meeting of shareholders for 2025 on September 4, 2025 [1] - The meeting approved the proposal regarding the repurchase and cancellation of certain restricted stocks granted under the 2023 restricted stock incentive plan that have not yet been released from restrictions [1]

Core Viewpoint - The legal opinion issued by Xinjiang Tianyang Law Firm confirms that the procedures for the convening and holding of the 2025 Second Extraordinary General Meeting of Shareholders of Guangzheng Eye Hospital Group Co., Ltd. comply with relevant laws and regulations, ensuring the legality and validity of the meeting [1][5][6] Group 1: Meeting Procedures - The board of directors announced the notice for the 2025 Second Extraordinary General Meeting on July 17, 2025, and a supplementary notice on August 22, 2025, detailing the meeting's agenda, date, and voting procedures [3][4] - The meeting was convened by the sixth board of directors and conducted through a combination of on-site and online voting, held at the designated company meeting room [4][5] Group 2: Attendance Qualifications - A total of 232 shareholders and their proxies attended the meeting, representing 135,062,596 shares, which accounts for 26.0504% of the company's total share capital [5] - The controlling shareholder, Guangzheng Investment Co., Ltd., holds 24.9136% of the shares and proposed a temporary agenda item for the meeting [4][5] Group 3: Voting Procedures - The meeting voted on three agenda items using both on-site and online voting methods, with all items passing by a majority of over two-thirds of the valid votes cast [5][6] - The results of the voting were announced immediately following the completion of the voting process [5] Group 4: Conclusion - The legal opinion concludes that all aspects of the meeting, including the convening procedures, qualifications of attendees, voting methods, and results, are in compliance with the Company Law, Securities Law, and the company's articles of association, thus affirming the meeting's legality [5][6]

光正眼科医院集团股份有限公司 关于回购注销部分限制性股票减少注册资本 光正眼科医院集团股份有限公司 证券代码：002524 证券简称：光正眼科 公告编号：2025-061 光正眼科医院集团股份有限公司 司自有资金。具体内容详见《光正眼科医院集团股份有限公司关于回购注销 2023 年限制性股票激励计划中部分激励对象已获授但尚未解除限售的限制性股票的 公告》（公告编号：2025-047）。 本次回购注销完成后，公司股份总数将由 518,467,074 股减少至 515,331,574 股，公司注册资本也将由 518,467,074 减少至 515,331,574 元。由于公司本次回购 注销部分限制性股票将涉及注册资本减少，根据《中华人民共和国公司法》（以 下简称"《公司法》"）等相关法律、法规的规定，公司特此通知债权人，债权人 自接到公司通知之日起 30 日内、未接到通知的自本公告披露之日起 45 日内，有 权要求本公司清偿债务或者提供相应的担保。债权人未在规定期限内行使上述权 利的，本次回购注销将按法定程序继续实施。公司债权人如要求本公司清偿债务 或提供相应担保的，应根据《公司法》等法律、法规的有关规定向本公司 ...

T&P 新疆天阳律师事务所 光正眼科 2025 年度第二次临时股东大会 2025 年度第二次临时股东大会 法律意见书 天阳证股字[2025]第 31 号 新疆天阳律师事务所 二○二五年九月 新疆天阳律师事务所 地址：新疆乌鲁木齐市水磨沟区红光山路 888 号绿城广场写字楼 2A 座 7 层 关于光正眼科医院集团股份有限公司 1 T&P 新疆天阳律师事务所 光正眼科 2025 年度第二次临时股东大会 新疆天阳律师事务所 关于光正眼科医院集团股份有限公司 法律意见书 天阳证股字[2025]第 31 号 致：光正眼科医院集团股份有限公司 新疆天阳律师事务所（下称"本所"）接受光正眼科医院集团股份有限公司 （下称"公司"）的委托，委派本所邵丽娅律师、李柯迪律师出席公司 2025 年 度第二次临时股东大会，根据《中华人民共和国公司法》（下称"《公司法》"）、 《中华人民共和国证券法》（下称"《证券法》"）、《上市公司股东会规则》 和《光正眼科医院集团股份有限公司章程》（下称"《公司章程》"），按照律 师行业公认的业务标准、道德规范和勤勉尽责精神，对有关的文件和事实进行核 查与验证，并出具法律意见。 本所律师已经对公司提 ...

光正眼科医院集团股份有限公司 证券代码：002524 证券简称：光正眼科 公告编号：2025-060 光正眼科医院集团股份有限公司 2025 年第二次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决议案的情况； 2、本次股东大会不涉及变更以往股东大会已通过的决议； 3、本次股东大会增加临时提案情况：2025 年 8 月 19 日，第六届董事会第 五次会议审议通过《关于工商变更企业类型并修订<公司章程>的议案》，同日公 司控股股东光正投资有限公司将审议通过后的上述议案以临时提案的方式提交 公司 2025 年第二次临时股东大会审议。对此，公司于 2025 年 8 月 22 日披露了 《关于持股 1%以上股东增加临时提案暨 2025 年度第二次临时股东大会补充通知 的公告》（公告编号：2025-058） 一、 会议召开情况 1.会议召开的日期、时间： 现场会议时间为：2025 年 9 月 4 日（星期四）下午 15:00； 网络投票时间为：2025 年 9 月 4 日。其中：通过深圳证券交易所交易系统 进行 ...

Core Viewpoint - The ophthalmology medical industry is experiencing a slowdown in the growth of refractive surgery revenue, with many companies reporting single-digit growth rates in this segment, while a few are still achieving double-digit growth. Group 1: Industry Overview - The refractive surgery business, a significant revenue source for private ophthalmology institutions, has shown a general trend of slowing growth in recent years [1] - Among five listed ophthalmology companies in A-shares, three reported refractive project revenue growth at single-digit levels or below in the first half of the year [1] - Specific growth figures include: - Puyi Eye Hospital (301239.SZ) with a 4.13% increase to 720 million yuan, accounting for 49% of total revenue [1] - He’s Eye Hospital (301103.SZ) with a 3.26% increase to 135 million yuan, accounting for 24% of total revenue [1] - Guangzheng Eye Hospital (002524.SZ) with a 0.32% increase to 142 million yuan, accounting for 32.71% of total revenue [1] - Aier Eye Hospital (300015.SZ) and Huaxia Eye Hospital (301267.SZ) are exceptions, achieving revenue growth rates of 11.4% and 13.75%, respectively [1] Group 2: Company Strategies - Aier Eye Hospital attributes its revenue growth in refractive projects to the acceptance of new surgical techniques such as All-Laser LASIK and the expansion of its medical network, enhancing patient coverage [3] - Puyi Eye Hospital is focusing on introducing authoritative expert teams and updating high-end diagnostic equipment to cultivate new growth points in the competitive refractive and vision care market [3] Group 3: Market Demand and Trends - The current refractive surgery patient population is divided into two categories: those with essential needs due to academic or professional requirements and those seeking aesthetic improvements [4] - Despite a stable demand from the essential needs group, the decision-making cycle for non-essential consumers is lengthening due to macroeconomic factors [4] - There is significant unmet demand in the refractive surgery market, with approximately 700 million myopic patients in China, but only about 1 million undergoing surgery annually [4] - The Z generation shows a personalized and urgent demand for vision correction, driving innovation and iteration in refractive surgery technologies [4] - Aierkon has introduced new refractive surgery solutions, such as All-Laser LASIK, which allows for personalized treatment based on various eye data [4] Group 4: Technology Adoption - Aierkon's All-Laser LASIK equipment has seen over 50,000 surgeries performed since its launch at the 2023 China International Import Expo, with over 100 hospitals equipped nationwide [5] - The company emphasizes the need for continued market education to enhance the penetration of new technologies [5]

Core Viewpoint - The refractive surgery business of private ophthalmology medical institutions is experiencing a slowdown in revenue growth, with several companies reporting single-digit growth rates in their refractive project revenues [1][2]. Group 1: Revenue Growth Analysis - Among five listed ophthalmology medical companies, three reported refractive project revenue growth at single-digit levels or below in the first half of the year. Specifically, Purui Eye Hospital (301239.SZ) saw a 4.13% increase to 720 million yuan, accounting for 49% of its total revenue; He’s Eye Hospital (301103.SZ) reported a 3.26% increase to 135 million yuan, making up 24% of its revenue; and Guangzheng Eye Hospital (002524.SZ) had a 0.32% increase to 142 million yuan, representing 32.71% of its revenue [1]. - In contrast, Aier Eye Hospital (300015.SZ) and Huaxia Eye Hospital (301267.SZ) managed to maintain double-digit growth rates in their refractive project revenues, with increases of 11.4% and 13.75%, respectively [1]. Group 2: Competitive Strategies - To navigate the competitive refractive surgery market, companies are leveraging new technologies. Aier Eye Hospital reported that its revenue growth in refractive projects is driven by the acceptance of new surgical techniques such as all-laser and full-femtosecond procedures, which have improved the business structure and increased average prices [2]. - Purui Eye Hospital is also responding to market competition by continuously introducing authoritative expert teams and updating high-end diagnostic equipment to cultivate new growth points [2]. Group 3: Market Demand and Trends - The current refractive surgery patient population can be divided into two groups: one with essential needs due to academic or professional requirements, and another seeking aesthetic improvements by eliminating glasses or contact lenses [2]. - Despite the large number of myopic patients in China, estimated at around 700 million, only about 1 million undergo refractive surgery annually, indicating significant unmet demand and potential for market penetration [3]. - The Z generation shows a personalized and urgent demand for vision correction, pushing for technological innovation and customization in refractive surgery [3].

Group 1 - The Shanghai Composite Index closed at 3872.93 points, above the six-month moving average, with a gain of 0.39% [1] - The total trading volume of A-shares reached 228.56 billion yuan [1] - A total of 76 A-shares have surpassed the six-month moving average today, with notable stocks including Sanjiang Shopping, Jinyun Laser, and Kexin Machinery, showing divergence rates of 7.87%, 5.15%, and 5.13% respectively [1] Group 2 - The stocks with the highest divergence rates from the six-month moving average include: - Sanjiang Shopping: 10.03% increase, 4.63% turnover rate, latest price 11.96 yuan, divergence rate 7.87% [1] - Jinyun Laser: 6.03% increase, 6.89% turnover rate, latest price 17.76 yuan, divergence rate 5.15% [1] - Kexin Machinery: 5.96% increase, 12.01% turnover rate, latest price 13.51 yuan, divergence rate 5.13% [1] - Other notable stocks with smaller divergence rates include: - Sanbian Technology, Shanghai Ailu, and George White, which have just crossed the six-month moving average [1]

Group 1 - The ophthalmology medical concept stocks experienced a surge during trading, with Sharplife reaching a limit up [1] - Xingqi Eye Medicine rose over 10% in the afternoon session [1] - Lifang Pharmaceutical previously hit the limit up, indicating strong market interest [1] Group 2 - Other companies such as Baicheng Pharmaceutical, Aibo Medical, Guangzheng Eye Care, and He Shi Eye Care also saw increases in their stock prices [1]